JP2018113985A5 - - Google Patents

Download PDF

Info

Publication number
JP2018113985A5
JP2018113985A5 JP2018073677A JP2018073677A JP2018113985A5 JP 2018113985 A5 JP2018113985 A5 JP 2018113985A5 JP 2018073677 A JP2018073677 A JP 2018073677A JP 2018073677 A JP2018073677 A JP 2018073677A JP 2018113985 A5 JP2018113985 A5 JP 2018113985A5
Authority
JP
Japan
Prior art keywords
cells
cell
gene
editing protein
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018073677A
Other languages
English (en)
Japanese (ja)
Other versions
JP6793146B2 (ja
JP2018113985A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018113985A publication Critical patent/JP2018113985A/ja
Publication of JP2018113985A5 publication Critical patent/JP2018113985A5/ja
Application granted granted Critical
Publication of JP6793146B2 publication Critical patent/JP6793146B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018073677A 2012-11-01 2018-04-06 細胞中でタンパク質を発現するための方法および生成物 Active JP6793146B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261721302P 2012-11-01 2012-11-01
US61/721,302 2012-11-01
US201361785404P 2013-03-14 2013-03-14
US61/785,404 2013-03-14
US201361842874P 2013-07-03 2013-07-03
US61/842,874 2013-07-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015540833A Division JP6510416B2 (ja) 2012-11-01 2013-11-01 細胞中でタンパク質を発現するための方法および生成物

Publications (3)

Publication Number Publication Date
JP2018113985A JP2018113985A (ja) 2018-07-26
JP2018113985A5 true JP2018113985A5 (cg-RX-API-DMAC7.html) 2018-09-06
JP6793146B2 JP6793146B2 (ja) 2020-12-02

Family

ID=50628111

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015540833A Active JP6510416B2 (ja) 2012-11-01 2013-11-01 細胞中でタンパク質を発現するための方法および生成物
JP2018073677A Active JP6793146B2 (ja) 2012-11-01 2018-04-06 細胞中でタンパク質を発現するための方法および生成物
JP2018073676A Active JP6890565B2 (ja) 2012-11-01 2018-04-06 細胞中でタンパク質を発現するための方法および生成物
JP2021027831A Active JP7436406B2 (ja) 2012-11-01 2021-02-24 細胞中でタンパク質を発現するための方法および生成物
JP2024018042A Pending JP2024056815A (ja) 2012-11-01 2024-02-08 細胞中でタンパク質を発現するための方法および生成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015540833A Active JP6510416B2 (ja) 2012-11-01 2013-11-01 細胞中でタンパク質を発現するための方法および生成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018073676A Active JP6890565B2 (ja) 2012-11-01 2018-04-06 細胞中でタンパク質を発現するための方法および生成物
JP2021027831A Active JP7436406B2 (ja) 2012-11-01 2021-02-24 細胞中でタンパク質を発現するための方法および生成物
JP2024018042A Pending JP2024056815A (ja) 2012-11-01 2024-02-08 細胞中でタンパク質を発現するための方法および生成物

Country Status (11)

Country Link
US (19) US9447395B2 (cg-RX-API-DMAC7.html)
EP (2) EP2914728B1 (cg-RX-API-DMAC7.html)
JP (5) JP6510416B2 (cg-RX-API-DMAC7.html)
KR (4) KR102121086B1 (cg-RX-API-DMAC7.html)
CN (1) CN104769112A (cg-RX-API-DMAC7.html)
AU (3) AU2013337651B2 (cg-RX-API-DMAC7.html)
BR (2) BR122019025681B1 (cg-RX-API-DMAC7.html)
CA (2) CA2890110C (cg-RX-API-DMAC7.html)
MX (2) MX363017B (cg-RX-API-DMAC7.html)
RU (2) RU2019143431A (cg-RX-API-DMAC7.html)
WO (1) WO2014071219A1 (cg-RX-API-DMAC7.html)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
PT4223311T (pt) 2011-05-24 2025-08-21 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Vacinas individualizadas para o cancro
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
SMT202200355T1 (it) 2011-12-16 2022-11-18 Modernatx Inc Composizioni di mrna modificato
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
EP2841572B1 (en) 2012-04-27 2019-06-19 Duke University Genetic correction of mutated genes
US9539307B2 (en) 2012-09-17 2017-01-10 The Research Institute At Nationwide Children's Hospital Compositions and methods for treating amyotrophic lateral sclerosis
CA2890110C (en) 2012-11-01 2023-05-02 Factor Bioscience Inc. Methods and products for expressing proteins in cells
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
CA2892391C (en) 2012-11-28 2023-10-17 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
ES2987399T3 (es) 2013-06-05 2024-11-14 Univ Duke Edición génica guiada por ARN y regulación génica
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
HRP20230015T1 (hr) * 2013-08-27 2023-02-17 Research Institute At Nationwide Children's Hospital Proizvodi i postupci liječenja amiotrofične lateralne skleroze
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. 低密度リポタンパク質受容体をコードするポリヌクレオチド
JP2016538276A (ja) 2013-11-05 2016-12-08 ザ・リサーチ・インスティテュート・アット・ネイションワイド・チルドレンズ・ホスピタルThe Research Institute At Nationwide Children’S Hospital 筋萎縮性側索硬化症の処置のためのNF−κBおよびSOD−1を阻害する組成物および方法
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
ES2821149T3 (es) * 2014-03-12 2021-04-23 Prec Biosciences Inc Eliminación del exón del gen de la distrofina mediante nucleasas modificadas genéticamente
RS66380B1 (sr) 2014-04-23 2025-02-28 Modernatx Inc Vakcine nukleinske kiseline
US10280419B2 (en) 2014-05-09 2019-05-07 UNIVERSITé LAVAL Reduction of amyloid beta peptide production via modification of the APP gene using the CRISPR/Cas system
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016049531A1 (en) 2014-09-26 2016-03-31 Purecircle Usa Inc. Single nucleotide polymorphism (snp) markers for stevia
CA3193811A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
US10195261B2 (en) 2014-11-26 2019-02-05 VaxLiant, LLC Adjuvant compositions and related methods
WO2016086222A1 (en) * 2014-11-26 2016-06-02 VaxLiant, LLC Adjuvant compositions and related methods
CA2969619A1 (en) 2014-12-03 2016-06-09 Agilent Technologies, Inc. Guide rna with chemical modifications
US10676726B2 (en) 2015-02-09 2020-06-09 Duke University Compositions and methods for epigenome editing
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
EP3543339A1 (en) 2015-02-13 2019-09-25 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2016154432A1 (en) 2015-03-24 2016-09-29 VaxLiant, LLC Adjuvant compositions and related methods
CA2981715A1 (en) 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Chemically modified guide rnas for crispr/cas-mediated gene regulation
US10676735B2 (en) 2015-07-22 2020-06-09 Duke University High-throughput screening of regulatory element function with epigenome editing technologies
EP4273782A3 (en) * 2015-07-25 2023-12-27 Frost, Habib A system, device and a method for providing a therapy or a cure for cancer and other pathological states
AU2016311454C1 (en) 2015-08-25 2023-10-19 Duke University Compositions and methods of improving specificity in genomic engineering using RNA-guided endonucleases
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
US11970710B2 (en) 2015-10-13 2024-04-30 Duke University Genome engineering with Type I CRISPR systems in eukaryotic cells
US20190218546A1 (en) 2015-10-16 2019-07-18 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
US11866754B2 (en) 2015-10-16 2024-01-09 Modernatx, Inc. Trinucleotide mRNA cap analogs
SG10202104041PA (en) 2015-10-23 2021-06-29 Harvard College Nucleobase editors and uses thereof
EP3384038B1 (en) * 2015-11-23 2024-07-24 The Regents of The University of Colorado, A Body Corporate Methods and compositions for reprogramming cells
EP3384055B1 (en) 2015-11-30 2025-07-16 Duke University Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
CN105494263B (zh) * 2015-12-25 2018-11-30 哈尔滨医科大学 一种产生ho-1/app/psen1三转基因阿尔茨海默病小鼠模型的方法
EP3411078A1 (en) * 2016-02-02 2018-12-12 Crispr Therapeutics AG Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
WO2017141109A1 (en) * 2016-02-18 2017-08-24 Crispr Therapeutics Ag Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
WO2017147278A1 (en) 2016-02-25 2017-08-31 The Children's Medical Center Corporation Customized class switch of immunoglobulin genes in lymphoma and hybridoma by crispr/cas9 technology
WO2017158422A1 (en) * 2016-03-16 2017-09-21 Crispr Therapeutics Ag Materials and methods for treatment of hereditary haemochromatosis
CA3018904C (en) * 2016-03-31 2024-04-02 Ethris Gmbh Novel minimal utr sequences
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
US12065667B2 (en) 2016-04-16 2024-08-20 Ohio State Innovation Foundation Modified Cpf1 MRNA, modified guide RNA, and uses thereof
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
CN109863143B (zh) 2016-07-13 2021-10-15 威泰克斯制药公司 提高基因组编辑效率的方法、组合物和试剂盒
US12214056B2 (en) 2016-07-19 2025-02-04 Duke University Therapeutic applications of CPF1-based genome editing
KR102827276B1 (ko) 2016-08-03 2025-07-01 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
CN116115629A (zh) 2016-08-17 2023-05-16 菲克特生物科学股份有限公司 核酸产品及其施用方法
CN106370765A (zh) * 2016-08-23 2017-02-01 国家烟草质量监督检验中心 一种基于反相色谱飞行时间质谱的喉癌尿液差异代谢物的测定筛选方法
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CN106381310B (zh) * 2016-08-31 2020-02-04 武汉华美生物工程有限公司 一种用t7噬菌体rna聚合酶和t7启动子系统在哺乳动物细胞表达蛋白的方法
CN110214180A (zh) 2016-10-14 2019-09-06 哈佛大学的校长及成员们 核碱基编辑器的aav递送
EP3538075A4 (en) * 2016-11-11 2020-08-05 Dnalite Therapeutics, Inc. GENE THERAPY STRUCTURES AND PROCESSES
KR101908593B1 (ko) * 2016-12-07 2018-10-16 연세대학교 산학협력단 Cftr 유전자 소실 유도 가이드 rna, cftr 변이를 갖는 t84 세포 및 이의 용도
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US20200040061A1 (en) * 2017-02-22 2020-02-06 Crispr Therapeutics Ag Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
WO2018160592A1 (en) * 2017-02-28 2018-09-07 Arcturus Therapeutics, Inc. Translatable molecules and synthesis thereof
US11168319B1 (en) * 2017-02-28 2021-11-09 Inari Agriculture Technology, Inc. Plant cell culture
JP2020510038A (ja) 2017-03-09 2020-04-02 プレジデント アンド フェローズ オブ ハーバード カレッジ がんワクチン
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
CN107475255B (zh) * 2017-03-21 2021-03-26 河北医科大学第二医院 一种基因载体介导的基于CRISPR/Cas9基因编辑系统的sgRNA及其用途
GB2575930A (en) 2017-03-23 2020-01-29 Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
WO2018227432A1 (en) * 2017-06-14 2018-12-20 Wuhan Institute Of Virology, Chinese Academy Of Sciences Cd2-associated protein (cd2ap) and its interactive proteins
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
AU2018352236B2 (en) 2017-10-16 2025-04-10 The Curators Of The University Of Missouri Treatment of amyotrophic lateral sclerosis (ALS)
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
EP3724214A4 (en) 2017-12-15 2021-09-01 The Broad Institute Inc. SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING
EP3728577A4 (en) 2018-01-22 2021-12-22 Inari Agriculture, Inc. PLANT GENE EDITING SYSTEMS, METHODS AND COMPOSITIONS
AU2019243155A1 (en) * 2018-03-27 2020-10-15 Factor Bioscience Inc. Nucleic acid-based therapeutics
US12312383B2 (en) 2018-04-18 2025-05-27 Altius Institute For Biomedical Sciences Animal pathogen-derived polypeptides and uses thereof for genetic engineering
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
CN108624592B (zh) * 2018-05-24 2021-08-17 苏州大学张家港工业技术研究院 针对DJ-1基因编辑的sgRNA筛选及其载体与应用
SG11202012770RA (en) * 2018-06-27 2021-01-28 Modernatx Inc Personalized cancer vaccine epitope selection
WO2020006126A1 (en) 2018-06-27 2020-01-02 Altius Institute For Biomedical Sciences Nucleic acid binding domains and methods of use thereof
CN108949830B (zh) * 2018-08-03 2021-11-26 福州大学 一种在鱼类中实现基因组编辑、精确定点基因敲入的方法
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
CN109628404B (zh) * 2018-12-18 2020-04-28 浙江大学 猪皮下脂肪前体细胞永生化细胞系的构建方法及用途
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
DE112020001306T5 (de) 2019-03-19 2022-01-27 Massachusetts Institute Of Technology Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CN110200973A (zh) * 2019-06-19 2019-09-06 南京市儿童医院 Dna依赖性蛋白激酶特异性抑制剂在制备防治肾纤维化药物中的用途
CN119569589A (zh) 2019-07-03 2025-03-07 菲克特生物科学股份有限公司 阳离子脂质及其用途
EP3999103A4 (en) 2019-07-19 2023-11-22 Inari Agriculture Technology, Inc. GENOMIC EDITING FOR ENHANCED HOMOLOGY-DIRECTED REPAIR
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
CN110699381A (zh) * 2019-09-17 2020-01-17 合肥瑞灵生物科技有限公司 地中海贫血病基因治疗载体构建方法及其用途
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021191678A1 (en) 2020-03-23 2021-09-30 Avectas Limited Engineering of dendritic cells for generation of vaccines against sars-cov-2
AU2021267940A1 (en) 2020-05-08 2022-12-08 President And Fellows Of Harvard College Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
CN113151181B (zh) * 2021-04-14 2022-11-29 中山大学附属第七医院(深圳) 一种脂肪干细胞重编程为神经元的方法及负载该神经元的细胞适应性水凝胶修复脊髓损伤
CN113373214B (zh) * 2021-06-18 2024-03-29 中国人民解放军军事科学院军事医学研究院 Cd30在诊断脑神经相关疾病中的用途
US11884915B2 (en) 2021-09-10 2024-01-30 Agilent Technologies, Inc. Guide RNAs with chemical modification for prime editing
CN114150017B (zh) * 2021-11-30 2023-05-16 长江大学 一种调节猪未成熟睾丸支持细胞乳酸分泌水平的方法及应用
CA3260237A1 (en) 2022-06-24 2023-12-28 Tune Therapeutics, Inc. Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression
CN119677858A (zh) * 2022-08-11 2025-03-21 益杰立科(上海)生物科技有限公司 一种表观编辑靶点的方法及用途
WO2025084896A1 (ko) * 2023-10-18 2025-04-24 연세대학교 산학협력단 신경세포 분화 유도용 재조합 벡터 및 이를 포함하는 퇴행성 뇌신경 질환의 예방 또는 치료용 약학적 조성물
CN118667815B (zh) * 2024-07-16 2025-02-14 宁夏大学 一种靶向prdm1改善牛子宫内膜炎的核苷酸序列及其应用

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539465A (en) 1968-10-08 1970-11-10 Ncr Co Encapsulation of hydrophilic liquid-in-oil emulsions
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6743771B2 (en) * 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
WO1998030679A1 (en) 1997-01-10 1998-07-16 Life Technologies, Inc. Embryonic stem cell serum replacement
JP2002508299A (ja) 1997-09-19 2002-03-19 セクイター, インク. センスmRNA治療
US20110171185A1 (en) 1999-06-30 2011-07-14 Klimanskaya Irina V Genetically intact induced pluripotent cells or transdifferentiated cells and methods for the production thereof
JP2004509970A (ja) 2000-09-26 2004-04-02 ハイブリドン・インコーポレイテッド 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節
WO2003018767A2 (en) 2001-08-27 2003-03-06 Advanced Cell Technology, Inc. Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
JPWO2003027277A1 (ja) 2001-09-21 2005-01-06 独立行政法人 科学技術振興機構 再プログラム化因子のスクリーニング方法、該方法によりスクリーニングされた再プログラム化因子および該再プログラム化因子を利用する方法、並びに、未分化融合細胞を分化させる方法および細胞、組織、臓器の製造方法
JP2005506074A (ja) 2001-10-18 2005-03-03 イクシオン・バイオテクノロジー・インコーポレーテッド 肝臓の幹細胞および前駆細胞の膵臓機能細胞への転換
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
GB0202149D0 (en) 2002-01-30 2002-03-20 Univ Edinburgh Pluripotency determining factors and uses thereof
EP2241572A3 (en) * 2003-06-03 2011-04-06 Eli Lilly And Company Modulation of survivin expression
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
GB2432846B (en) 2004-09-08 2009-12-30 Wisconsin Alumni Res Found Medium and culture of embryonic stem cells
US7442548B2 (en) 2004-09-08 2008-10-28 Wisconsin Alumni Research Foundation Culturing human embryonic stem cells in medium containing pipecholic acid and gamma amino butyric acid
WO2006081249A2 (en) * 2005-01-25 2006-08-03 Cell Therapeutics, Inc. Conjugates of biologically active proteins having a modified in vivo half-life
EP1904528B1 (en) * 2005-07-13 2012-10-31 Novo Nordisk Health Care AG Host cell protein knock-out cells for production of therapeutic proteins
WO2007014275A2 (en) * 2005-07-26 2007-02-01 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
EP3354723B1 (en) 2005-08-29 2023-12-13 Technion Research & Development Foundation Ltd. Media for culturing stem cells
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
CN101864392B (zh) 2005-12-13 2016-03-23 国立大学法人京都大学 核重新编程因子
WO2007079886A1 (de) 2005-12-22 2007-07-19 Csl Behring Gmbh Oktanoatreduziertes human albumin
DE102006051516A1 (de) * 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
GB0623635D0 (en) 2006-11-27 2007-01-03 Stem Cell Sciences Uk Ltd Pluripotent cell growth media
US20080213377A1 (en) 2006-12-08 2008-09-04 Bhatia Sangeeta N Delivery of Nanoparticles and/or Agents to Cells
US10829733B2 (en) 2007-01-04 2020-11-10 Biolamina Ab Composition and method for enabling proliferation of pluripotent human stem cells
EP2099911A2 (en) 2007-01-11 2009-09-16 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
WO2008097926A2 (en) 2007-02-02 2008-08-14 Yale University Transient transfection with rna
CA2684242C (en) 2007-03-23 2019-11-12 Wisconsin Alumni Research Foundation Somatic cell reprogramming
MX352541B (es) 2007-04-07 2017-11-29 Whitehead Inst Biomedical Res Reprogramación de células somáticas.
AU2008286249B2 (en) 2007-12-10 2013-10-10 Kyoto University Efficient method for nuclear reprogramming
EP2072618A1 (en) 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Use of RNA for reprogramming somatic cells
CA2718904C (en) 2008-03-17 2017-01-03 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
US20110045001A1 (en) 2008-03-28 2011-02-24 Biontex Laboratories Gmbh Transfection results of non-viral gene delivery systems by influencing of the innate immune system
JP2011518555A (ja) * 2008-04-14 2011-06-30 サンガモ バイオサイエンシーズ, インコーポレイテッド 標的組込みのための線形ドナーコンストラクト
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
CA2954948A1 (en) 2008-06-04 2009-12-10 Cellular Dynamics International, Inc. Methods for the production of ips cells using non-viral approach
GB2460552B (en) 2008-06-05 2011-09-07 Iti Scotland Ltd Stem cell culture media and methods
US8669048B2 (en) 2008-06-24 2014-03-11 Parkinson's Institute Pluripotent cell lines and methods of use thereof
US20100184033A1 (en) 2008-07-16 2010-07-22 West Michael D Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby
EP2326711A2 (en) 2008-08-20 2011-06-01 VIRxSYS Corporation Compositions and methods for generation of pluripotent stem cells
US8268620B2 (en) 2008-10-24 2012-09-18 Wisconsin Alumni Research Foundation OCT4 and SOX2 with SV40 T antigen produce pluripotent stem cells from primate somatic cells
ES2561949T3 (es) * 2008-11-21 2016-03-01 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Reprogramación de células hacia un estado pluripotente
US20110023141A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved with parkinson's disease
WO2010079340A2 (en) 2009-01-08 2010-07-15 Eisai R & D Management Co., Ltd. Assay
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
US8219348B2 (en) 2009-01-22 2012-07-10 Johnson Controls Technology Company Method for calibrating and/or correcting a display device having a needle, the needle being able to move in rotation about an axis of rotation
WO2010093655A2 (en) 2009-02-10 2010-08-19 University Of Dayton Enhanced method for producing stem-like cells from somatic cells
US10894944B2 (en) 2009-04-10 2021-01-19 Monash University Cell culture media
EP2421957B1 (en) 2009-04-22 2020-11-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US10837020B2 (en) 2009-04-22 2020-11-17 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long RNA molecules
EP2421563B1 (en) 2009-04-22 2017-04-12 Massachusetts Institute of Technology Innate immune suppression enables repeated delivery of long rna molecules
US8496941B2 (en) 2009-06-03 2013-07-30 National Institute Of Advanced Industrial Science And Technology Vectors for generating pluripotent stem cells and methods of producing pluripotent stem cells using the same
EP2459231B1 (de) * 2009-07-31 2016-06-08 Ethris Gmbh Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression
US8802437B2 (en) * 2009-09-24 2014-08-12 Cellectis Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
US9340772B2 (en) * 2009-10-29 2016-05-17 Mcmaster University Generating induced pluripotent stem cells and progenitor cells from fibroblasts
JP5898086B2 (ja) 2009-11-04 2016-04-06 セルラー ダイナミクス インターナショナル, インコーポレイテッド 化学物質を用いるエピソームリプログラミング
CN102712904A (zh) 2009-11-11 2012-10-03 桑福德—伯恩哈姆医学研究协会 用于产生和调节iPS细胞的方法及其组合物
KR102505097B1 (ko) 2009-12-07 2023-03-02 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 세포 리프로그래밍을 위한 정제된 변형 rna를 포함하는 rna 제제
US20130189741A1 (en) 2009-12-07 2013-07-25 Cellscript, Inc. Compositions and methods for reprogramming mammalian cells
HUE041436T2 (hu) * 2009-12-10 2019-05-28 Univ Minnesota Tal-effektor-közvetített DNS-módosítás
US8557972B2 (en) 2009-12-21 2013-10-15 University Of Washington Through Its Center For Commercialization Compositions and methods for transfection of RNA and controlled stabilization of transfected RNA
US8962331B2 (en) * 2010-02-01 2015-02-24 The Board Of Trustees Of The Leland Stanford Junior University Method of making induced pluripotent stem cell from adipose stem cells using minicircle DNA vectors
WO2011110886A1 (en) 2010-03-09 2011-09-15 Biolamina Ab Composition and method for enabling proliferation of pluripotent human stem cells
EP3072961A1 (en) 2010-04-16 2016-09-28 Children's Medical Center Corporation Sustained polypeptide expression from synthetic, modified rnas and uses thereof
WO2011140397A2 (en) 2010-05-05 2011-11-10 The Regents Of The University Of California Office Of The President Stem cell defined media for xeno-free and feeder free conditions and uses thereof
US20130145487A1 (en) * 2010-05-12 2013-06-06 Cellectis Meganuclease variants cleaving a dna target sequence from the dystrophin gene and uses thereof
US8048675B1 (en) 2010-05-12 2011-11-01 Ipierian, Inc. Integration-free human induced pluripotent stem cells from blood
WO2011146121A1 (en) 2010-05-17 2011-11-24 Sangamo Biosciences, Inc. Novel dna-binding proteins and uses thereof
EP2392208B1 (en) * 2010-06-07 2016-05-04 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease and their use
WO2011159369A1 (en) * 2010-06-14 2011-12-22 Iowa State University Research Foundation, Inc. Nuclease activity of tal effector and foki fusion protein
EP2582794B2 (en) * 2010-06-15 2024-04-24 FUJIFILM Cellular Dynamics, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
CN108531444A (zh) 2010-08-05 2018-09-14 威斯康星校友研究基金会 用于人多能细胞培养的简化基础培养基
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
WO2012021632A2 (en) * 2010-08-10 2012-02-16 The Johns Hopkins University Generation and use of pluripotent stem cells
GB201014169D0 (en) * 2010-08-25 2010-10-06 Cambridge Entpr Ltd In vitro hepatic differentiation
US9447408B2 (en) 2010-09-14 2016-09-20 Kyoto University Method of efficiently establishing induced pluripotent stem cells
EP2622090B1 (en) * 2010-09-27 2019-06-19 Sangamo Therapeutics, Inc. Compositions for inhibiting viral entry into cells
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
EP2625278A1 (en) * 2010-10-08 2013-08-14 Regents of the University of Minnesota A method to increase gene targeting frequency
JP5888753B2 (ja) 2010-11-04 2016-03-22 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
US9267123B2 (en) 2011-01-05 2016-02-23 Sangamo Biosciences, Inc. Methods and compositions for gene correction
US9499592B2 (en) 2011-01-26 2016-11-22 President And Fellows Of Harvard College Transcription activator-like effectors
KR20120096395A (ko) * 2011-02-22 2012-08-30 주식회사 툴젠 뉴클레아제에 의해 유전자 변형된 세포를 농축시키는 방법
MX363013B (es) * 2011-02-25 2019-03-04 Recombinetics Inc Animales genéticamente modificados y métodos para su obtención.
CN103502436A (zh) 2011-03-07 2014-01-08 麻省理工学院 用核酸转染细胞的方法
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
WO2012138453A1 (en) * 2011-04-03 2012-10-11 The General Hospital Corporation Efficient protein expression in vivo using modified rna (mod-rna)
CN103608027B (zh) * 2011-04-05 2016-01-20 赛莱蒂克斯公司 用于生成致密tale-核酸酶的方法及其用途
WO2013003475A1 (en) 2011-06-27 2013-01-03 Cellscript, Inc. Inhibition of innate immune response
CA2841165A1 (en) 2011-07-11 2013-01-17 Cellular Dynamics International, Inc. Methods for cell reprogramming and genome engineering
EP2758529B1 (en) * 2011-09-21 2019-03-20 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
CA2858148C (en) * 2011-12-05 2023-03-14 Factor Bioscience Inc. Methods and products for transfecting cells
SMT202200355T1 (it) 2011-12-16 2022-11-18 Modernatx Inc Composizioni di mrna modificato
CA2859691A1 (en) 2011-12-21 2013-06-27 Moderna Therapeutics, Inc. Methods of increasing the viability or longevity of an organ or organ explant
PL3144389T3 (pl) 2011-12-30 2018-10-31 Cellscript, Llc WYTWARZANIE I STOSOWANIE ZSYNTETYZOWANEGO IN VITRO ssRNA DO WPROWADZANIA DO SSACZYCH KOMÓREK W CELU INDUKCJI EFEKTU BIOLOGICZNEGO LUB BIOCHEMICZNEGO
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
EP2834357B1 (en) * 2012-04-04 2017-12-27 Life Technologies Corporation Tal-effector assembly platform, customized services, kits and assays
AU2013246419A1 (en) 2012-04-10 2014-10-30 City Of Hope RNA aptamers for therapeutic and diagnostic delivery to pancreatic cancer cells
CA2885576A1 (en) 2012-04-24 2013-10-31 The Brigham And Women's Hospital, Inc. Generating pluripotent cells de novo
US9738879B2 (en) * 2012-04-27 2017-08-22 Duke University Genetic correction of mutated genes
US10119150B2 (en) 2012-05-13 2018-11-06 Allele Biotechnology & Pharmaceuticals, Inc. Feeder-free Derivation of human-induced pluripotent stem cells with synthetic messenger RNA
ES2729563T3 (es) 2012-05-13 2019-11-04 Allele Biotechnology & Pharmaceuticals Inc Derivación sin alimentadores de células madre pluripotentes inducidas humanas con ARN mensajero sintético
US10155929B2 (en) 2012-05-13 2018-12-18 Allele Biotechnology & Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
EP2872625B1 (en) * 2012-07-11 2016-11-16 Sangamo BioSciences, Inc. Methods and compositions for the treatment of lysosomal storage diseases
EP2684892A1 (en) * 2012-07-13 2014-01-15 Association Française contre les Myopathies Compositions and methods for duchenne muscular dystrophy gene therapy
JP6401704B2 (ja) * 2012-10-10 2018-10-10 サンガモ セラピューティクス, インコーポレイテッド T細胞を修飾する化合物およびその使用
CA2890110C (en) * 2012-11-01 2023-05-02 Factor Bioscience Inc. Methods and products for expressing proteins in cells
WO2014081855A1 (en) * 2012-11-20 2014-05-30 Universite De Montreal Methods and compositions for muscular dystrophies
HK1215873A1 (zh) * 2012-12-05 2016-09-23 桑格摩治疗股份有限公司 調整代謝紊亂的方法及組合物
JP2016514953A (ja) 2013-02-22 2016-05-26 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー テロメア伸長に関する化合物、組成物、方法及びキット
ES2987399T3 (es) * 2013-06-05 2024-11-14 Univ Duke Edición génica guiada por ARN y regulación génica
CN104878020B (zh) 2015-04-29 2017-09-15 华中农业大学 一种控制水稻叶片直立性发育的基因及其应用
CN116115629A (zh) * 2016-08-17 2023-05-16 菲克特生物科学股份有限公司 核酸产品及其施用方法

Similar Documents

Publication Publication Date Title
JP2018113985A5 (cg-RX-API-DMAC7.html)
Kaji et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors
Staahl et al. Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes
EP3294873B2 (en) Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
Okita et al. Generation of germline-competent induced pluripotent stem cells
RU2020104969A (ru) Способы и продукты для получения и доставки нуклеиновых кислот
JP2017035113A5 (cg-RX-API-DMAC7.html)
RU2017118312A (ru) Способы и препараты для трансфекции клеток
US20090191171A1 (en) Reprogramming of Differentiated Progenitor or Somatic Cells Using Homologous Recombination
Sułkowski et al. Introduction of exogenous HSV-TK suicide gene increases safety of keratinocyte-derived induced pluripotent stem cells by providing genetic “emergency exit” switch
JP2019058176A (ja) 新規方法
CN110467679A (zh) 一种融合蛋白、碱基编辑工具和方法及其应用
Wang Application of modified mRNA in somatic reprogramming to pluripotency and directed conversion of cell fate
Nguyen et al. Patient-specific iPSC-derived RPE for modeling of retinal diseases
Pietronave et al. Advances and applications of induced pluripotent stem cells
WO2009092042A1 (en) Reprogramming of differentiated progenitor or somatic cells using homologous recombination
CN109486814A (zh) 一种用于修复HBB1基因点突变的gRNA、基因编辑系统、表达载体和基因编辑试剂盒
JP7606176B2 (ja) ゲノム編集効率を向上させる融合タンパク質及びその使用
CN109536494A (zh) 一种用于修复HBB1基因点突变的gRNA、基因编辑系统、表达载体和基因编辑试剂盒
US20190136200A1 (en) Cellular Reprogramming Utilizing mRNA
Tian et al. Rationale and methodology of reprogramming for generation of induced pluripotent stem cells and induced neural progenitor cells
US20230272348A1 (en) Methods of generating hematopoietic cell preparations
Gjaltema et al. KRAB-induced heterochromatin effectively silences PLOD2 gene expression in somatic cells and is resilient to TGFβ1 activation
JP7630116B2 (ja) 変異型klfタンパク質、及び誘導多能性幹細胞の製造方法
EP3806873A1 (en) Reprogramming cells with synthetic messenger rna